** Shares of Innovent Biologics Inc 1801.HK rise 3.3% to HK$31, on course to snap two consecutive session of decline
** Stock on track for the biggest one-day jump since Dec. 9, 2024; among top 10 gainers in healthcare index .HSCIH, which is up 0.8%
** Innovent says new drug application of limertinib - the third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has received approval by National Medical Products Administration of China (NMPA) for treatment of lung cancer
** Hang Seng Commerce & Industry Index .HSNC and Hang Seng Index .HSI boht slip 0.1%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。